CA-DENODO
2.9.2020 09:02:09 CEST | Business Wire | Press release
Denodo , the leader in data virtualization, today announced increased adoption of its Coronavirus Data Portal (CDP), an open, cooperative effort that utilizes data virtualization to unify critical datasets originally exposed in different formats from multiple sources and countries. Originally developed in March during early onset of the pandemic, Denodo has combined and unified COVID-19 related intelligence and made it available to data consumers such as data scientists, analysts, and researchers who are leveraging the information to find solutions to this global disease. For more information, and to participate in the effort, visit https://www.coronavirusdataportal.com .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200902005272/en/
“In an effort to measure and monitor the health of our employees, we needed to create a way for them to tell us about their own health and to provide the clinical teams and leadership with details on who is healthy and who is not before coming to work,” said Mahendra Parasmal, Sr. Information Architect at Spectrum Health . “Denodo provides us with the ability to connect self-purported health data provided by employees via an online survey with employee demographics, employee hierarchy, badge system & Active Directory data virtually. This delivers wellness information in near real-time without having to Extract, Transform & Load the data physically from source systems or run batch incremental loads. As a result, we have been able to speed up our overall build time by at least 3x and deliver the end result in weeks instead of months.”
Free of charge to participants, the Coronavirus Data Portal enables organizations and institutions to share their individual data sets that Denodo integrates and offers to the broader community for consumption via the data platform. It also allows members to integrate and curate these data sets so they can augment their own COVID-19 initiatives. As of today, there are 64 sources, 220 datasets, and 441 views offered on CDP.
“I can personally attest to how our company was able to leverage Denodo’s Coronavirus Data Portal having developed a COVID-19 virtual hub that provides reports based on data science and pmOne Share ,” said Dr. Norman Bernhardt, Head of Digital Solutions R&D, pmOne . “pmOne Share Cockpit aggregates existing and established reporting solutions and provides advanced filtering capabilities, which data scientists can use to develop algorithms to analyze global news flows, the results of which are displayed in a dashboard.”
More specifically, Denodo’s CDP is being used to:
- Search the Curated Datasets: Coronavirus Data Portal offers a catalog of the curated data sets - both uploaded and curated by Denodo data stewards and those contributed by users of the data portal. This allows users to search the available data sets and find the data relevant to them such as details about the spread of the disease, school closures, financial impact, etc. It also enables them to drill deeper to view details about a particular data set and its relationship with other ones.
- Enhance Dashboard BI Tools with Integrated Data Portal: CDP supports BI tools such as Power BI, Tableau and others so participants can connect to the data portal and generate smart visualizations. Users can use these tools to easily create new customized reports of the integrated data.
- Extend Data integration Using API Service/Downloadable CSV Datasets: Lets users further integrate their application with the Coronavirus Data Platform, utilizing it as an API service layer. This enables users to access the curated data sets in a variety of views and is an option that is growing significantly as more and more multi-faceted data is added from across the globe.
- Contribute to the Initiative: The Coronavirus Data Portal is an open platform, which permits users to contribute their own data sets to the initiative. It suggests data sources that should be added to the Data Portal and Denodo’s data steward team will review the data and usage permissions to determine if it’s appropriate to be uploaded. Alternatively, they can create new data sets by combining the Coronavirus Data Portal data with their own data and share this new data set with other Data Portal users.
“While our data stewards and data engineers have been working behind the scenes to add more data sets to the Coronavirus Data Portal, we have also been getting some great suggestions from the user community. Based on suggestions, we’ve added COVID-19 forecast data, real-time information about how many are infected and where, school closures, global news as they are published, and much more,” said Angel Viña, CEO and Founder at Denodo. “Contributing data sets - either through suggestions or by creating derived data sets - will continue the growth of the Coronavirus Data Portal and enhance the value that fellow users are getting from using the data. This continued growth will provide more varied and richer data for all of us to use and share in our efforts to combat this deadly pandemic.”
Please Tweet: News: #datavirtulization provider @denodo offers complimentary #coronavirus data portal to unify #datasets and information to fight #COVID19
About Denodo
Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200902005272/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES and CANAL+ Strengthen Strategic Partnership Through 204027.10.2026 08:50:00 CET | Press release
SES and CANAL+, the global media and entertainment group, have extended their strategic partnership through 2040 with a multi-year agreement covering capacity across Europe, Africa and the Caribbean. Under the renewed agreement, CANAL+ will leverage SES’s satellite infrastructure across several orbital positions to deliver premium video and pay TV services to a global subscriber base that now exceeds 40 million viewers across 70 countries. "SES has been a trusted partner for more than 30 years, helping us deliver premium content to millions of viewers across Europe and Africa. This new agreement supports our long-term growth and provides the flexibility and reliability required as we continue to expand our international footprint and serve an increasingly diverse subscriber base," said Stéphane Baumier, Chief Technology Officer of CANAL+. "CANAL+ is one of SES's most valued and longest-standing customers. This agreement demonstrates the enduring importance of satellite in reliably deli
Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer27.10.2026 08:30:00 CET | Press release
Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 First EU approval of Enhertu in the curative-intent early breast cancer setting Third approval for Enhertu in the EU in four months Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for
Avanzanite Bioscience Expands UK Presence and Appoints Sarah O’Connell as Country Manager27.10.2026 08:00:00 CET | Press release
Avanzanite Bioscience B.V., a European pharmaceutical company focused on rare diseases, today announced the expansion of its United Kingdom (UK) presence and the appointment of Sarah O’Connell as UK Country Manager. The move strengthens Avanzanite’s long-term commitment to the UK and its ability to help eligible patients access innovative rare disease medicines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027035012/en/ Sarah O'Connell, Country Manager, UK, Avanzanite Bioscience “The UK is essential to our ambition of building Avanzanite into a European rare disease champion. We feel a deep and lasting connection to this market and there is no European reach without the UK,” said Adam Plich, co-founder and CEO, Avanzanite Bioscience. “At a time when parts of the life sciences sector are reassessing their investment and presence in the UK, we are choosing to commit and build for the long term. With Sarah’s extensive rare
LTM Secures Strategic Engagement with a Global Banking and Financial Services Firm27.10.2026 05:30:00 CET | Press release
LTM, the Business Creativity partner to the world's largest enterprises, has secured a strategic engagement with a large global banking and financial services firm, further strengthening its position as a trusted technology and transformation partner to leading financial institutions. This two-year engagement is already underway with an option to extend for an additional year and has a potential value of up to USD 100 million. The engagement reflects the continued expansion of LTM’s relationship with the client and its growing role in advancing strategic technology programmes and supporting supplier consolidation initiatives across the organization. Under the agreement, LTM will serve as a preferred partner driving the consolidation and delivery of strategic technology requirements across key wealth, personal banking, and global functions. The engagement will leverage LTM’s deep banking-domain expertise, engineering excellence, and global delivery capabilities to support the client’s t
DDN Selected to Modernize Research Data Infrastructure at UNSW Sydney26.10.2026 22:30:00 CET | Press release
DDN EXAScaler and Arcitecta Mediaflux will replace 11 legacy storage systems, simplifying access to research data while balancing performance and cost DDN, the global leader in AI and data intelligence solutions, today announced that UNSW Sydney has selected DDN to deliver a new research data storage environment as part of the university’s Research Data Experience (RDE) program. Working with Australian software company Arcitecta, DDN will combine its EXAScaler parallel file system with Arcitecta’s Mediaflux® data management platform to help researchers spend less time managing data and more time using it. Following an extensive 18-month evaluation, UNSW selected an integrated approach that will replace 11 legacy storage systems with a coordinated environment for high-performance storage and enterprise data management. The decision reflects a broader challenge facing research-intensive institutions: how to support rapidly expanding scientific datasets while simplifying infrastructure, i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom